Predictive Oncology Inc. (POAI) - Dilution Analysis

10-Q filing | 10.4M shares outstanding

10-K filing | 5.5M shares outstanding

S-3/A filing: This prospectus relates to the possible resale, from time to time by the selling stockholders named in this prospectus, of up to an aggregate of 2,547,789 shares of our common stock and 3,422,392 shares of common stock underlying warrants.

S-3 filing: This prospectus relates to the possible resale, from time to time, by the selling stockholders of shares of common stock and shares of common stock underlying warrants.

S-3 filing: This prospectus relates to the possible resale, from time to time by the selling stockholders named in this prospectus, of up to an aggregate of 14,903,393 shares of our common stock underlying pre-funded warrants.

8-K filing: Stock split 1-for-15 | Outstanding: 10,892,429 → 726,161

10-Q filing | 10.9M shares outstanding

S-1 filing: This S-1 filing relates to the resale of common stock by YA II PN, LTD. and the potential issuance of additional shares to them under a standby equity purchase agreement.

8-K filing: Predictive Oncology Inc. entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing the Company to sell up to $10 million of its common stock. The company also issued 120,482 shares of common stock to the investor as a commitment fee.

10-Q filing | 8.9M shares outstanding

10-K filing | 8.9M shares outstanding

8-K filing: Predictive Oncology entered into an extension agreement with Renovaro, where Renovaro is acquiring 467,290 shares of Predictive Oncology's common stock for $500,000 and agreed to purchase an additional 901,298 shares for $964,389 upon the execution of a definitive agreement. ($0.5M proceeds)

8-K filing: Predictive Oncology Inc. sold 363,336 shares of common stock at $1.50 per share in a registered direct offering, resulting in gross proceeds of approximately $545,004. ($0.55M proceeds)

8-K filing: Predictive Oncology Inc. entered into a binding letter of intent with Renovaro, Inc. for Predictive Oncology to be acquired by Renovaro in exchange for preferred stock of Renovaro. ($2.49M proceeds)

10-Q filing | 6.4M shares outstanding

S-3 filing: The filing is an S-3 form indicating the company may offer additional shares of common stock or other securities convertible into common stock to raise capital and will receive proceeds from the exercise of warrants for cash, planning to use the net proceeds for general corporate purposes and working capital.

10-Q filing | 6.7M shares outstanding

8-K filing: Predictive Oncology Inc. closed warrant exercises resulting in gross proceeds of approximately $1.26 million and issued new Series A and Series B warrants and Placement Agent Warrants. ($1.26M proceeds)

S-3/A filing: The company may offer and sell, in one or more offerings, up to $200,000,000 in any combination of debt securities, common stock, preferred stock, warrants, units, or subscription rights. They are also offering common stock through an at-the-market offering with H.C. Wainwright & Co., LLC for up to $3,696,000.

10-Q filing | 4.1M shares outstanding

S-3 filing: The filing is for a mixed shelf offering of up to $200,000,000 in debt securities, common stock, preferred stock, warrants, units, or subscription rights, and a common stock offering with aggregate offering price of up to $3,696,000 through H.C. Wainwright & Co., LLC.

10-K filing | 4.0M shares outstanding

10-Q filing | 4.0M shares outstanding

10-Q filing | 4.0M shares outstanding

10-Q filing | 4.0M shares outstanding

10-K filing | 73.0M shares outstanding

10-Q filing | 78.4M shares outstanding

S-1 filing: This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus of up to an aggregate of 4,737,280 shares of our common stock, par value $0.01 per share.

10-Q filing | 78.2M shares outstanding

8-K filing: Predictive Oncology Inc. completed two registered direct offerings, selling a total of 12,000,000 shares of common stock at $0.60 per share, with concurrent private placements of warrants and amendments to existing warrants, generating gross proceeds of approximately $7.2 million for working capital purposes. ($7.2M proceeds)

10-Q filing | 65.8M shares outstanding

10-K filing | 65.6M shares outstanding

10-Q filing | 65.4M shares outstanding

8-K filing: The company's stockholders approved an increase in the number of authorized shares of common stock from 100,000,000 to 200,000,000. Investor warrants for 15,520,911 shares and placement agent warrants for 1,164,068 shares became exercisable.

10-Q filing | 65.3M shares outstanding

8-K filing: Predictive Oncology Inc. entered into a Securities Purchase Agreement to issue and sell 15,520,911 shares of common stock and warrants at a combined offering price of $1.375 per share and warrant, for gross proceeds of $21,341,252.63 in a registered direct offering. ($21.34M proceeds)

10-Q filing | 49.8M shares outstanding

S-3 filing: The company is filing an S-3 to register shares of common stock, shares of preferred stock, warrants to purchase common stock or preferred stock, one or more series of debt securities, and units consisting of a combination of the foregoing for an aggregate initial offering price of up to $250,000,000.

S-3/A filing: This S-3/A filing relates to the offer and resale of up to 16,671,747 shares of the company's common stock by selling stockholders and the registered direct offering an aggregate of 4,222,288 shares of its common stock.

10-K filing | 48.8M shares outstanding

S-3 filing: This prospectus relates to the offer and resale of up to 16,671,747 shares of common stock by selling stockholders and also includes information regarding prior direct offering.

8-K filing: Predictive Oncology Inc. sold 9,043,766 shares of common stock at $1.95 per share in a private placement, with each share also receiving a warrant to purchase one-half of a share at $2.00 per share. ($17.64M proceeds)

8-K filing: Predictive Oncology Inc. entered into a Securities Purchase Agreement to issue and sell 4,222,288 shares of its common stock at $1.75 per share in a registered direct offering, for gross proceeds of $7,389,004 and agreed to issue warrants to purchase up to 2,111,144 shares of common stock. ($7.39M proceeds)

S-1/A filing: Predictive Oncology Inc. files an S-1/A Registration Statement to register for resale up to 9,713,526 shares of common stock on behalf of the selling stockholder, pursuant to an Equity Purchase Agreement with Oasis Capital, LLC.

S-1 filing: This prospectus relates to the offer and resale of up to 9,713,526 shares of our common stock by Oasis Capital, LLC. The company also agreed to issue and sell in a registered direct offering an aggregate of 2,200,000 shares of its common stock, at a purchase price of $1.00 per share, for gross proceeds of approximately $2.2 million and $4.1 million at a price of $1.20.

S-1 filing: This S-1 filing relates to the offer and resale of up to 5,661,128 shares of common stock by selling stockholders, a registered direct offering of 2,200,000 shares at $1.00 per share with warrants, a registered direct offering of 2,200,000 shares at $1.20 per share with warrants, and a private placement involving common stock and warrants.

8-K filing: Predictive Oncology Inc. entered into a Securities Purchase Agreement to issue and sell 3,414,970 shares of common stock at $1.20 per share in a registered direct offering, for gross proceeds of $4,097,964, and agreed to issue warrants to purchase up to 1,707,485 shares of common stock. ($4.1M proceeds)

8-K filing: Predictive Oncology Inc. entered into a Securities Purchase Agreement to issue and sell 2,200,000 shares of common stock at $1.00 per share in a registered direct offering, for gross proceeds of $2.2 million, and agreed to issue warrants to purchase up to 1,100,000 shares of common stock. ($2.2M proceeds)

8-K filing: Predictive Oncology Inc. entered into a Securities Purchase Agreement on January 8, 2021, to issue and sell 3,655,840 shares of common stock at $0.842 per share in a registered direct offering, with gross proceeds of approximately $3.074 million. ($3.07M proceeds)

10-Q filing | 17.7M shares outstanding

8-K filing: Predictive Oncology Inc. entered into amendments with L2 Capital, LLC and Oasis Capital, LLC to extend the maturity dates of promissory notes and increase the principal amounts. The Oasis Capital notes can be converted into shares of common stock with a cap on the number of shares issuable.

8-K filing: Predictive Oncology Inc. amended warrants to purchase common stock, adjusting the fundamental transactions and exercise price of certain warrants.

8-K filing: Predictive Oncology Inc. amended warrants to purchase up to 1,424,506 shares of common stock, originally issued in connection with the merger with Helomics Holding Corporation, to allow exercise at a price of $0.845 per share, adjusted from $10.00 per share due to a 1-for-10 reverse stock split on October 29, 2019.

POS AM filing: This POS AM filing from September 14, 2020, provides an update on the company's common stock outstanding and details of a previous Series E convertible preferred stock private placement.

10-Q filing | 15.2M shares outstanding

S-3 filing: This S-3 filing relates to the offer and resale of up to 1,396,826 shares of the company's common stock by selling stockholders.

8-K filing: Predictive Oncology Inc. acquired substantially all of the assets owned by Quantitative Medicine LLC in exchange for 954,719 shares of common stock valued at approximately $1,750,000. The company also agreed to extensions of the maturity date of secured promissory notes. ($1.75M proceeds)

8-K filing: Predictive Oncology Inc. entered into Warrant Exercise Letter Agreements with accredited institutional investors to exercise warrants for 1,396,826 shares of Common Stock at $1.45 per share, and will issue new warrants to purchase up to an equal number of shares at $1.80 per share. ($2.2M proceeds)

S-1 filing: This prospectus relates to the offer and resale of up to 3,288,073 shares of our common stock by Oasis Capital, LLC.

S-1/A filing: This prospectus relates to the offer and resale of up to 1,738,357 shares of our common stock by the selling stockholders.

S-1 filing: This prospectus relates to the offer and resale of up to 1,738,357 shares of our common stock by the selling stockholders as listed in the selling stockholders table on page 13.

10-Q filing | 10.6M shares outstanding

8-K filing: Predictive Oncology Inc. completed the acquisition of assets from InventaBioTech, Inc., Soluble Therapeutics, Inc., and BioDtech, Inc. by issuing 125,000 shares of its common stock and releasing obligations under a Security Agreement and Promissory Note.

8-K filing: Predictive Oncology Inc. entered into a Securities Purchase Agreement to issue and sell 1,396,826 shares of common stock at $1.575 per share in a registered direct offering, for gross proceeds of approximately $2.2 million. ($2.2M proceeds)

8-K filing: Predictive Oncology Inc. exchanged a promissory note with Carl Schwartz, the Company's CEO, for 1,533,481 newly issued shares of common stock at $1.43 per share. ($2.19M proceeds)

S-3/A filing: This S-3/A filing relates to the offer and resale of up to 5,889,561 shares of common stock by selling stockholders.

S-3 filing: This prospectus relates to the offer and resale of up to 5,889,561 shares of our common stock by the selling stockholders.

10-K filing | 5.8M shares outstanding

8-K filing: Predictive Oncology Inc. amended promissory notes with L2 Capital, LLC and Oasis Capital, LLC, including issuing 30,000 shares of common stock to Oasis Capital, LLC in exchange for a waiver of rights.

8-K filing: Predictive Oncology Inc. entered into a securities purchase agreement for the sale of up to 1,650,165 shares of common stock and warrants in a private placement. ($3.19M proceeds)

8-K filing: Predictive Oncology Inc. entered into a Securities Purchase Agreement with Oasis Capital, LLC, issuing a convertible promissory note for up to $1,450,000 in exchange for a $1,200,000 cash investment and issued 46,875 shares of its common stock to the Investor.

8-K filing: Predictive Oncology Inc. entered into an Exchange Agreement with Carl Schwartz, where Schwartz exchanged existing notes and warrants for a new promissory note of $2,115,000 and 50,000 shares of common stock. ($0.13M proceeds)